Creo Medical Group PLC (LON:CREO) said its US-approved precision device that effectively microwaves tumours was used to treat a pancreatic cancer patient as part of a first-in-human study.
The procedure was carried out by Dr Carlos Robles-Medranda in Ecuador on a patient with an unresectable pancreatic neuroendocrine tumour that couldn’t be treated using traditional surgical techniques.
The successful operation using the Creo MicroBlate Fine device was designed to improve quality of life and life expectancy rather than being curative.
Pancreatic cancer is one of the most pernicious forms of the disease and carries an extremely poor prognosis.
“The outcome of the procedure was a success, with subsequent follow up scans not only showing no return of the tumour, but also an absence of any obvious scar tissue,” said chief executive Craig Gulliford.